Assessing the Activity of Multidrug Resistance-Associated Protein 1 at the Lung Epithelial Barrier.


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
11 2020
Historique:
received: 24 02 2020
accepted: 19 03 2020
pubmed: 15 4 2020
medline: 10 3 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Multidrug resistance-associated protein 1 (adenosine triphosphate-binding cassette subfamily C member 1 [ABCC1]) is abundantly expressed at the lung epithelial barrier, where it may influence the pulmonary disposition of inhaled drugs and contribute to variability in therapeutic response. The aim of this study was to assess the impact of ABCC1 on the pulmonary disposition of 6-bromo-7-

Identifiants

pubmed: 32284394
pii: jnumed.120.244038
doi: 10.2967/jnumed.120.244038
doi:

Substances chimiques

6-bromo-7-methylpurine 0
Carbon Radioisotopes 0
Multidrug Resistance-Associated Proteins 0
Propionates 0
Purines 0
Quinolines 0
verlukast 5Q9O54P0H7
multidrug resistance-associated protein 1 Y49M64GZ4Q

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1650-1657

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Severin Mairinger (S)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Johannes A Sake (JA)

School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

Irene Hernández Lozano (I)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; and.

Thomas Filip (T)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Michael Sauberer (M)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Johann Stanek (J)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Thomas Wanek (T)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Carsten Ehrhardt (C)

School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

Oliver Langer (O)

Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria oliver.langer@ait.ac.at.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; and.
Division of Nuclear Medicine, Department of Biomedical Imaging und Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH